Predictability of metabolism of ibuprofen and naproxen using chimeric mice with human hepatocytes

Drug Metabolism and Disposition

Volumn 40, Issue 12, 2012, Pages 2267-2272

  Sanoh, Seigo ^a   Horiguchi, Aya ^a   Sugihara, Kazumi ^c   Kotake, Yaichiro ^a   Tayama, Yoshitaka ^c   Uramaru, Naoto ^d   Ohshita, Hiroki ^e   Tateno, Chise ^b,e   Horie, Toru ^f   Kitamura, Shigeyuki ^d   Ohta, Shigeru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^d NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

^e PhoenixBio USA Corporation   (Japan)

^f DeThree Research Laboratories   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; AMINO ACID N ACYLTRANSFERASE; CYTOCHROME P450; GLUCURONOSYLTRANSFERASE; IBUPROFEN; NAPROXEN; SULFOTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG METABOLISM; DRUG URINE LEVEL; HUMAN; HUMAN CELL; LIVER; LIVER CELL; MALE; METABOLITE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SPECIES DIFFERENCE; URINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHIMERA; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTES; HUMANS; IBUPROFEN; MALE; METABOLIC DETOXICATION, DRUG; METABOLOME; MICE; MICE, SCID; MICROSOMES, LIVER; NAPROXEN; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; MUS; RATTUS;

EID: 84869128749     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.047555     Document Type: Article

References (36)

1. Anderson S, Luffer-Atlas D, and Knadler MP (2009) Predicting circulating human metabolites: how good are we? Chem Res Toxicol 22:243-256.
2. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, and Miners JO (2005) S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423-433.
3. Brown HS, Griffin M, and Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35:293-301.
4. Buchheit D, Dragan CA, Schmitt EI, and Bureik M (2011) Production of ibuprofen acyl glucosides by human UGT2B7. Drug Metab Dispos 39:2174-2181.
5. Chiba M, Ishii Y, and Sugiyama Y (2009) Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 11:262-276.
6. Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, et al. (2009) Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357-368.
7. +/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 41:464-475.
8. Emoto K, Tateno C, Hino H, Amano H, Imaoka Y, Asahina K, Asahara T, and Yoshizato K (2005) Efficient in vivo xenogeneic retroviral vector-mediated gene transduction into human hepatocytes. Hum Gene Ther 16:1168-1174.
9. Falany CN, Ström P, and Swedmark S (2005) Sulphation of O-desmethylnaproxen and related compounds by human cytosolic sulfotransferases. Br J Clin Pharmacol 60:632-640.
10. Fagerholm U (2007) Prediction of human pharmacokinetics - evaluation of methods for prediction of hepatic metabolic clearance. J Pharm Pharmacol 59:803-828.
11. Hallifax D, Foster JA, and Houston JB (2010) Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res 27:2150-2161.
12. Hamman MA, Thompson GA, and Hall SD (1997) Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 54:33-41.
13. 3H-warfarin using chimeric mice with humanized liver. Drug Metab Pharmacokinet 24:153-160.
14. Katoh M, Matsui T, Nakajima M, Tateno C, Kataoka M, Soeno Y, Horie T, Iwasaki K, Yoshizato K, and Yokoi T (2004) Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32:1402-1410.
15. Katoh M, Matsui T, Okumura H, Nakajima M, Nishimura M, Naito S, Tateno C, Yoshizato K, and Yokoi T (2005) Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 33:1333-1340.
16. Katoh M and Yokoi T (2007) Application of chimeric mice with humanized liver for predictive ADME. Drug Metab Rev 39:145-157.
17. Kepp DR, Sidelmann UG, Tjørnelund J, and Hansen SH (1997) Simultaneous quantitative determination of the major phase I and II metabolites of ibuprofen in biological fluids by high-performance liquid chromatography on dynamically modified silica. J Chromatogr B Biomed Sci Appl 696:235-241.
18. Kitamura S, Nitta K, Tayama Y, Tanoue C, Sugihara K, Inoue T, Horie T, and Ohta S (2008) Aldehyde oxidase-catalyzed metabolism of N1-methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:1202-1205.
19. Kola I and Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715.
20. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894.
21. Mills RF, Adams SS, Cliffe EE, Dickinson W, and Nicholson JS (1973) The metabolism of ibuprofen. Xenobiotica 3:589-598.
22. Nagilla R, Frank KA, Jolivette LJ, and Ward KW (2006) Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance. J Pharmacol Toxicol Methods 53:106-116.
23. Nishimura M, Yoshitsugu H, Yokoi T, Tateno C, Kataoka M, Horie T, Yoshizato K, and Naito S (2005) Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver. Xenobiotica 35:877-890.
24. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
25. Okumura H, Katoh M, Sawada T, Nakajima M, Soeno Y, Yabuuchi H, Ikeda T, Tateno C, Yoshizato K, and Yokoi T (2007) Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci 97:533-538.
26. 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab Dispos 24:126-136.
27. Sanoh S, Horiguchi A, Sugihara K, Kotake Y, Tayama Y, Ohshita H, Tateno C, Horie T, Kitamura S, and Ohta S (2012a) Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. Drug Metab Dispos 40:322-328.
28. Sanoh S, Nozaki K, Murai H, Terashita S, Teramura T, and Ohta S (2012b) Prediction of human metabolism of FK3453 by aldehyde oxidase using chimeric mice transplanted with human or rat hepatocytes. Drug Metab Dispos 40:76-82.
29. Shirley MA, Guan X, Kaiser DG, Halstead GW, and Baillie TA (1994) Taurine conjugation of ibuprofen in humans and in rat liver in vitro. Relationship to metabolic chiral inversion. J Pharmacol Exp Ther 269:1166-1175.
30. Stringer R, Nicklin PL, and Houston JB (2008) Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. Xenobiotica 38:1313-1329.
31. Sugawara Y, Fujihara M, Miura Y, Hayashida K, and Takahashi T (1978) Studies on the fate of naproxen. II. Metabolic fate in various animals and man. Chem Pharm Bull 26:3312-3321.
32. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, et al. (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901-912.
33. Yamasaki C, Kataoka M, Kato Y, Kakuni M, Usuda S, Ohzone Y, Matsuda S, Adachi Y, Ninomiya S, Itamoto T, et al. (2010) In vitro evaluation of cytochrome P450 and glucuronidation activities in hepatocytes isolated from liver-humanized mice. Drug Metab Pharmacokinet 25:539-550.
34. Yamazaki H, Kuribayashi S, Inoue T, Tateno C, Nishikura Y, Oofusa K, Harada D, Naito S, Horie T, and Ohta S (2010) Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5- a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. Chem Res Toxicol 23:152-158.
35. Yoshitsugu H, Nishimura M, Tateno C, Kataoka M, Takahashi E, Soeno Y, Yoshizato K, Yokoi T, and Naito S (2006) Evaluation of human CYP1A2 and CYP3A4 mRNA expression in hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet 21:465-474.
36. i/AUC) ratios. Drug Metab Dispos 32:1201-1208.